BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2424206)

  • 1. Evaluation of an antibody to human milk fat globule antigen in the detection of metastatic carcinoma in pleural, pericardial and peritoneal fluids.
    Hilborne LH; Cheng L; Nieberg RK; Lewin KJ
    Acta Cytol; 1986; 30(3):245-50. PubMed ID: 2424206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive effusion cytology as the initial presentation of malignancy.
    Monte SA; Ehya H; Lang WR
    Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology of fluids from pleural, peritoneal and pericardial cavities in children. A comprehensive survey.
    Hallman JR; Geisinger KR
    Acta Cytol; 1994; 38(2):209-17. PubMed ID: 8147212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
    Schofield K; D'Aquila T; Rimm DL
    Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differential cytology of effusions using monoclonal antibodies].
    Lüttges J; Neumann K; Pflüger KH; Schmitz-Moormann P
    Pathologe; 1988 May; 9(3):137-42. PubMed ID: 2457213
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibody HMFG-2 retains activity in vivo and binds to high molecular weight components expressed by metastatic breast cancers.
    Griffiths AB; Padmanabhan N; Shepherd P; Lazarus C; Maisey M; Fentiman I; Rubens R; Taylor-Papadimitriou J
    Mol Biol Med; 1986 Oct; 3(5):425-35. PubMed ID: 3550364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunofluorescent staining of metastatic carcinoma cells in serious fluid with carcinoembryonic antibody, epithelial membrane antibody, AUA-1 and Ber-EP4.
    Illingworth AL; Young JA; Johnson GD
    Cytopathology; 1994 Oct; 5(5):270-81. PubMed ID: 7819512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of cancer cells in peritoneal fluid or washing by immunocytochemical staining with monoclonal antibodies].
    Zhao Y
    Zhonghua Fu Chan Ke Za Zhi; 1992 May; 27(3):159-61, 189. PubMed ID: 1382925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytological variations observed in the malignant cells in body cavity fluids].
    Matsuda M
    Rinsho Byori; 1990 Nov; Suppl 87():69-85. PubMed ID: 2287091
    [No Abstract]   [Full Text] [Related]  

  • 11. The cell block for body cavity fluids: do the results justify the cost?
    Jonasson JG; Ducatman BS; Wang HH
    Mod Pathol; 1990 Nov; 3(6):667-70. PubMed ID: 1702212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of human milk fat globule antigens HMFG1 and HMFG2 on ovarian tumours and lung tumours.
    Hay FG; Leonard RC
    Dis Markers; 1988 Mar; 6(1):29-39. PubMed ID: 2456176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies.
    Ghosh AK; Spriggs AI; Taylor-Papadimitriou J; Mason DY
    J Clin Pathol; 1983 Oct; 36(10):1154-64. PubMed ID: 6194183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of tumor cells in body cavity fluids by flow cytometric and immunocytochemical analysis.
    Krishan A; Ganjei-Azar P; Jorda M; Hamelik RM; Reis IM; Nadji M
    Diagn Cytopathol; 2006 Aug; 34(8):528-41. PubMed ID: 16850481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant effusions: from diagnosis to biology.
    Davidson B
    Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
    Lee BH; Hecht JL; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of immunohistochemistry staining and cytologic diagnosis by using cell block sections prepared with effusion fluid cytology specimens].
    Mao YY; Yang M; Liu DG; Lin MH; Zhang LQ; Chen ZQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):547-50. PubMed ID: 20021967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of AgNOR technique in the interpretation of serous effusions].
    Rocher AE; Blanco AM; Palaoro LA
    Rev Med Chil; 2000 Sep; 128(9):963-8. PubMed ID: 11349500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.
    Davidson B; Risberg B; Berner A; Nesland JM; Tropé CG; Kristensen GB; Bryne M; Goscinski M; van de Putte G; Flørenes VA
    Gynecol Oncol; 2001 Nov; 83(2):249-56. PubMed ID: 11606079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.